CAR peptide for improved coronavirus survival
AssigneeVascular Biosciences
InventorDavid Mann
Life of this patent
Estimating the term…
Abstract
A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.
Claims5
A method of treating an individual suffering from a disease, the method comprising:
- (a) providing a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof;
- (b) providing at least one therapeutic molecule selected from the group consisting of a steroid, sivelestat, and anti-thrombin III (ATIII) which conveys a measurable therapeutic benefit to a disease selected from the group consisting of sepsis, septic shock, acute respiratory distress syndrome, pneumonitis, and secondary bacterial pneumonia;
- (c) co-administering a composition comprising a) and b) to an individual in need thereof;
- and
- (d) measuring a therapeutic benefit to the individual;
- wherein the disease is sepsis resulting from coronavirus infection.
Dependencies are inferred from the claim text.